Skip to Main Content

++

INTRODUCTION

++

terconazole (ter-kon-a-zole)

Terazol-3, Terazol-7

Classification

Therapeutic: antifungals (vaginal)

Pharmacologic: triazoles

++
Indications
++

Treatment of vulvovaginal candidiasis.

++
Action
++

Affects the permeability of the fungal cell wall, allowing leakage of cellular contents. Not active against bacteria. Therapeutic Effects: Inhibited growth and death of susceptible Candida, with ↓ in accompanying symptoms of vulvovaginitis (vaginal burning, itching, discharge).

++
Adverse Reactions/Side Effects
++

GI: abdominal pain. GU: dysmenorrhea, irritation, itching, vulvovaginal burning. Misc: fever.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor patient's symptoms to help document drug effectiveness.

++
Interventions
++

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection.

++
Patient/Client-Related Instruction
++

  • Advise patient to report any increased local sensitivity to this drug (pain, burning, itching, swelling) or other adverse reactions (fever, abdominal pain, menstrual problems).

  • Therapeutic response for vaginal infections is usually seen after 1 wk. Advise patient that application is typically continued throughout the full course of therapy even if feeling better. Therapy should be continued during menstrual period.

  • Advise patient to seek medical help if infections persist or recur after the full treatment. Recurrent fungal infections may be a sign of systemic illness.

++
Pharmacokinetics
++

Absorption: 5–16% is systemically absorbed following intravaginal administration.

++

Distribution: Unknown. Action is primarily local.

++

Metabolism and Excretion: Negligible with local application.

++

Half-life: Not applicable.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (plasma concentrations)

ROUTE ONSET PEAK DURATION
intravaginal unknown 6.6 hr unknown

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity to active ingredients, additives, or preservatives.

++

Use Cautiously in: OB/Lactation: Safety not established.

++
Interactions
++

Drug-Drug: Not known.

++
Route/Dosage
++

Vag (Adults): Vaginal cream—1 applicatorful (5 g) of 0.4% cream hs for 7 days or 1 applicatorful (5 g) of 0.8% cream hs for 3 days. Vaginal suppositories—1 suppository (80 mg) hs for 3 days.

++
Availability (generic available)
++

Vaginal cream: 0.4% Rx, 0.8% Rx. Vaginal suppositories: 80 mg Rx.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.